Siegfried Holding AG

Swiss Stock Exchange:SFZN.SW

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

🔬 Chemicals & Advanced Materials

🌿 Fertilizers

💊 Pharmaceuticals

Location

Switzerland

Market Cap

USD 4.88 B

Share Price

USD 111.46

Avg Daily Volume

90,504

Change (1 day)

0.81%

Change (1 year)

-89.19%

Change (YTD)

-89.78%

Siegfried Holding AG Free Cash Flow Yield on June 27, 2025: -0.27%

Siegfried Holding AG Free Cash Flow Yield is -0.27% on June 27, 2025, a -114.13% change year over year. Free cash flow yield compares the return from free cash flow to the market cap; higher yield suggests attractive investment.

Siegfried Holding AG 52-week low Free Cash Flow Yield is 1.91% on June 27, 2025, which is 803.68% above the current Free Cash Flow Yield.
Siegfried Holding AG 52-week low Free Cash Flow Yield is -0.32% on June 27, 2025, which is -19.12% below the current Free Cash Flow Yield.
Siegfried Holding AG average Free Cash Flow Yield for the last 52 weeks is 0.89%.

Daily

From:

To:

Zoom:

Key data

Date	Free Cash Flow Yield	Dividend Yield	Market Capitalization	Share Price

Swiss Stock Exchange: SFZN.SW

Siegfried Holding AG

CEO	Mr. Marcel Imwinkelried
IPO Date	April 14, 1995
Location	Switzerland
Headquarters	Untere Bruehlstrasse 4
Employees	3,886
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology 🔬 Chemicals & Advanced Materials 🌿 Fertilizers 💊 Pharmaceuticals

Description

Siegfried Holding AG engages in the life sciences business worldwide. The company develops and produces active pharmaceutical ingredients (APIs) and intermediates, as well as finished dosage forms, including solid oral dosage forms, and sterile and aseptic filling injectables, ophthalmics, and inhalative products. It offers contract development and manufacturing services, including pharmaceutical and analytical development, process and analytical transfer, commercial manufacturing and packaging, and scale up and clinical trial material production. In addition, the company provides APIs and controlled substances focusing on anesthetics, pain treatment applications, and central nervous and respiratory diseases. Further, it licenses oral solid and sterile products; assembles registration dossiers; and offers a common technical document for various products. The company was founded in 1873 and is headquartered in Zofingen, Switzerland.